Mazdutide: indexed trial records
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
This page carries 12 of the 58 records the literature query returned for Mazdutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.
Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.
At a glance
- Class
- Incretin receptor agonists
- Receptor targets as recorded
- GLP-1 receptor, Glucagon receptor
- Records indexed here
- 12
- Records returned by the query
- 58
- Publication years covered
- 2025–2026
- Query retrieved
- 2026-10-12
Shape of the indexed record set
| Record class | Records |
|---|---|
| Phase 3 | 4 |
| Phase 2 | 1 |
| Phase 1 | 1 |
| Trial, no phase assigned | 1 |
| Review or synthesis | 4 |
| Not a registered trial record | 1 |
| Study model as assigned | Records |
|---|---|
| human trial | 6 |
| other | 5 |
| rodent | 1 |
Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.
Endpoint coverage
| Endpoint | Records for this compound | Records across all compounds in scope |
|---|---|---|
| Body weight and adiposity | 11 | 108 |
| Glycaemic control | 9 | 117 |
| Cardiovascular | 0 | 30 |
| Renal | 0 | 10 |
| Hepatic | 0 | 9 |
| Neurological | 1 | 18 |
Derived record-set tier
Human trial evidence
(INFERRED, derived from record counts)
Basis: 6 of 12 indexed records are interventional human trials by their own assigned publication type.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of
study quality or of consensus, and it does not rank one compound above another.
What the corpus does not carry for this compound
- Identity fields with no source retrieved: uniprot_id, sequence.
- Reported half-life: no source retrieved, so the value reads Unknown.
- Amounts reported in the cited literature: no row recorded.
- Adverse effects reported in the cited literature: no row recorded.
- Long-form mechanism: not written, because no source was read in full.
- Records the query returned that this corpus does not carry: 46.
An absent row records the absence of a retrieved report, never the absence of the thing itself.
Application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
The records
Phase 3 — 4 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 2 | pmid:41407859 | 2026 | Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Humans; Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Peptides; Receptors, Glucagon; Placebos; Hypoglycemic Agents |
| 3 | pmid:41407860 | 2026 | Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature · Clinical Trial, Phase III, Comparative Study | human trial | Humans; Diabetes Mellitus, Type 2; Body Weight; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Adult |
| 7 | pmid:42251595 | 2026 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA · Clinical Trial, Phase III, Multicenter Study | human trial | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Diarrhea; Nausea; Vomiting |
| 9 | pmid:40421736 | 2025 | Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Humans; Obesity; Weight Loss; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Body Mass Index; Treatment Outcome |
Phase 2 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 6 | pmid:41875890 | 2026 | Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial Med (New York, N.Y.) · Clinical Trial, Phase II, Randomized Controlled Trial | human trial | Humans; Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Body Mass Index; Treatment Outcome; Double-Blind Method |
Phase 1 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 11 | pmid:40832785 | 2025 | Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial Diabetes, obesity & metabolism · research-article, Clinical Trial, Phase I | human trial | Humans; Obesity; Body Weight; Weight Loss; Peptides; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous |
Trial, no phase assigned — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 1 | pmid:41260459 | 2026 | Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial Contemporary clinical trials · Clinical Trial Protocol | other | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
Review or synthesis — 4 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 4 | pmid:41804840 | 2026 | Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials Diabetes, obesity & metabolism · Meta-Analysis, Review | other | Humans; Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Hypoglycemic Agents; Treatment Outcome; Adult |
| 5 | pmid:41820018 | 2026 | Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes Expert opinion on therapeutic patents · Review | other | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents |
| 8 | pmid:42410325 | 2026 | Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Peptides; Receptors, Glucagon; Hypoglycemic Agents |
| 12 | pmid:41028652 | 2025 | Mazdutide: First Approval Drugs · Review | other | Humans; Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents; Drug Approval |
Not a registered trial record — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 10 | pmid:40479843 | 2025 | Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis EBioMedicine · research-article | rodent | Brain; Animals; Humans; Mice; Diabetes Mellitus, Type 2; Disease Models, Animal; Peptides; Receptors, Glucagon |
Where this page sits
Receptor targets
- GLP-1 receptor: every compound in scope acting at it
- Glucagon receptor: every compound in scope acting at it
Curated pairs
All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.
Review status
- Review tier
- High impact
- State
- Pending qualified review
- Compiled by
- automated pipeline
- Qualified clinical review
- None on record
Why this tier was assigned
- 6 indexed record(s) are interventional human trials
- the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus
Checks the pipeline performed
- every cited source id resolves to a sources[] row on the entity
- every identifier is a well-formed PMID or DOI
- study model derived only from assigned MeSH headings and publication types
- banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
- unknown values render as the literal word Unknown
Checks the pipeline did not perform
- no full text was read
- no clinical appraisal of any study
- no assessment of whether the indexed set is representative of the literature
A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.
Sources
- PubChem Compound Summary for CID 167312357, Mazdutide. PubChem, National Library of Medicine (2026). pubchem:167312357
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:mazdutide
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine (2021). pmid:34430840
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications (2022). pmid:35750681
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine (2022). pmid:36247927
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature communications (2023). pmid:38092790
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care (2024). pmid:37943529
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England journal of medicine (2025). pmid:40421736
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407859
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407860
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology (2024). pmid:38440786